The following is a press release.
FRAMINGHAM – Arch Therapeutics, Inc., a developer of novel liquid, gel and solid hemostatic and wound care devices, today, May 13, announced the pricing of registered direct offering of approximately 8.6 million units, each unit consisting of a share of the Company’s common stock, and a Series H Warrant (“Series H Warrant”) to purchase 1 (one) share of our common stock for the combined purchase price of $0.325 per unit.
The Series H Warrants have an exercise price of $0.40 per share and are exercisable for a period of five years.
Headquartered in Framingham, Arch Therapeutics, Inc. is a biotechnology company developing an approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care.
Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients.
The gross proceeds to Arch from this offering are approximately $2.8 million before deducting estimated offering expenses payable by the Company.
The offering is expected to close on or about May 14, 2019, subject to customary closing conditions.
The securities described above are being offered by Arch pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”) (File Number 333- 213878) on October 20, 2016.